About: Clinical features of COVID‐19 convalescent patients with re‐positive nucleic acid detection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical features of COVID‐19 convalescent patients with re‐positive nucleic acid detection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical features of COVID‐19 convalescent patients with re‐positive nucleic acid detection
Creator	Chen, Min Cai, Ting Zhu, Hui Chen, \| Zhang, \| Fan, Lingyan Chen, Tongen Fu, Liyun Hu, Yaoren Jin, Jiachang Jin, Yinhua Kang, Junfei Shao, Jiale Xiong, Zi Ye, Honghua Ying, Jun Zhe, \| Zheng, Nanhong
Source	Medline; PMC
abstract	BACKGROUND: Coronavirus disease 2019 (COVID‐19) is a pandemic that has rapidly spread worldwide. Increasingly, confirmed patients being discharged according to the current diagnosis and treatment protocols, follow‐up of convalescent patients is important to knowing about the outcome. METHODS: A retrospective study was performed among 98 convalescent patients with COVID‐19 in a single medical center. The clinical features of patients during their hospitalization and 2‐week postdischarge quarantine were collected. RESULTS: Among the 98 COVID‐19 convalescent patients, 17 (17.3%) were detected positive severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) nucleic acid during 2‐week postdischarge quarantine. The median time from discharge to SARS‐CoV‐2 nucleic acid re‐positive was 4 days (IQR, 3‐8.5).The median time from symptoms onset to final respiratory SARS‐CoV‐2 detection of negative result was significantly longer in re‐positive group (34 days [IQR, 29.5‐42.5]) than in non‐re‐positive group (19 days [IQR, 16‐26]). On the other hand, the levels of CD3‐CD56 + NK cells during hospitalization and 2‐week postdischarge were higher in re‐positive group than in non‐re‐positive group (repeated measures ANOVA, P = .018). However, only one case in re‐positive group showed exudative lesion recurrence in pulmonary computed tomography (CT) with recurred symptoms. CONCLUSION: It is still possible for convalescent patients to show positive for SARS‐CoV‐2 nucleic acid detection, but most of the re‐positive patients showed no deterioration in pulmonary CT findings. Continuous quarantine and close follow‐up for convalescent patients are necessary to prevent possible relapse and spread of the disease to some extent.
has issue date	2020-06-07(xsd:dateTime)
bibo:doi	10.1002/jcla.23392
bibo:pmid	32506726
has license	cc-by-nc-nd
sha1sum (hex)	bbd0e43002baf8192c0f203b6d2b0b0210819857
schema:url	https://doi.org/10.1002/jcla.23392
resource representing a document's title	Clinical features of COVID‐19 convalescent patients with re‐positive nucleic acid detection
has PubMed Central identifier	PMC7300578
has PubMed identifier	32506726
schema:publication	J Clin Lab Anal
resource representing a document's body	covid:bbd0e43002baf8192c0f203b6d2b0b0210819857#body_text
is schema:about of	named entity 'diagnosis' named entity 'PANDEMIC' named entity 'CD56' named entity 'patients' named entity 'However' named entity 'discharged' named entity 'convalescent' named entity 'retrospective study' named entity 'exudative' named entity 'lactic dehydrogenase' named entity 'CT imaging' named entity 'nasopharyngeal swab' named entity 'Wuhan' named entity 'hypertension' named entity 'CDC' named entity 'upper lobe' named entity 'Tiantong temple' named entity 'CT imaging' named entity 'hospital discharge' named entity '23.5%' named entity 'SARS-CoV-2' named entity 'radiologists' named entity 'antiviral treatment' named entity 'blood count' named entity 'procalcitonin' named entity 'CT scanning' named entity 'arbidol' named entity 'exudative' named entity 'Mann-Whitney U test' named entity 'CD3' named entity 'inflammation' named entity 'COVID-19' named entity 'COVID-19' named entity 'Wuhan' named entity 'lopinavir' named entity 'Biotechnology' named entity 'fever' named entity 'epidemiological' named entity 'IL-6' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'colloidal gold' named entity 'follow-up' named entity 'symptoms and signs' named entity 'University of Chinese Academy of Sciences' named entity 'assay' named entity 'standard deviation' named entity 'respiratory symptoms' named entity 'Laboratory testing' named entity 'SARS-CoV-2' named entity 'nucleic acid detection' named entity 'lymphocyte count' named entity 'Mann-Whitney U test' named entity 'serum' named entity 'respiratory symptoms' named entity 'two-way analysis of variance' named entity 'Fisher's exact test' named entity 'TNF-a' named entity 'LDH' named entity 'Epidemiological' named entity 'significant difference' named entity 'CD3' named entity 'lesion' named entity 'COVID-19' named entity 'Sputum'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software